Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241813743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Aleksei S Ponomarev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kazan Federal University, KFU.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease that is characterized by progressive muscle atrophy (degeneration), including skeletal muscles in charge of the ability to move. SMA is caused by defects in the SMN1 gene (Survival of Motor Neuron 1) which encodes a protein crucial for the survival and functionality of neuron cells called motor neurons. Decreased level of functioning SMN protein leads to progressive degeneration of alpha-motor neurons performing muscular motility. Over the past decade, many strategies directed for SMN-level-restoration emerged, such as gene replacement therapy (GRT), CRISPR/Cas9-based gene editing, usage of antisense oligonucleotides and small-molecule modulators, and all have been showing their perspectives in SMA therapy. In this review, modern SMA therapy strategies are described, making it a valuable resource for researchers, clinicians and everyone interested in the progress of therapy of this serious disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
ORCID-Profile: Daria S Chulpanova, Valeriya V Solovyeva, Albert A Rizvanov
Förderung
- Kazan Federal University
- KFU
Zitieren
APA
Ponomarev, A. S., Chulpanova, D. S., Yanygina, L. M., Solovyeva, V. V., & Rizvanov, A. A. (2023). Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813743
Vancouver
Ponomarev AS, Chulpanova DS, Yanygina LM, Solovyeva VV, Rizvanov AA. Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813743
BibTeX
@article{Ponomarev2023,
author = {Ponomarev, Aleksei S and Chulpanova, Daria S and Yanygina, Lina M and Solovyeva, Valeriya V and Rizvanov, Albert A},
title = {Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241813743}
}
EUVIMED